Zoetis receives positive opinion from cvmp for portela® (relfovetmab) to alleviate pain associated with osteoarthritis in cats

Parsippany, n.j.--(business wire)---- $zts #animalhealth--if approved, zoetis' portela will be the first long-acting anti-ngf mab therapy for cats and is designed to provide 3 months of oa pain relief.

ZTS Ratings Summary

ZTS Quant Ranking